Connecting Biological Research to Clinical Therapy
GE Healthcare works with customers to help them
Fast forward thirty years and lives will be significantly
Solutions for cell and protein manipulation
GE Healthcare build tools used to manipulate genes,
|from understanding the biological basis of diseases to
guiding drug development to treat them.
GE Healthcarebioprocessing solutions support
GE Healthcare offers customers scalable solutions
Harnessing bioprocess expertise to advance future medicine
One area GE is betting on is regenerative medicine, cell and immunotherapies. With these treatments, doctors can address the underlying causes of disease, essentially teaching a patien’s body to heal itself.
Life Sciences’ Cell Therapy business is industrializing the tools and processes needed to bring these new therapies into mainstream clinical practice, investing in the field for the long-term, and partnering with pharma, biotech and clinical researchers.
GE Healthcare has the required combination of biological, engineering and industrial capabilities to accelerate the field into the mainstream. Only by being affordable and efficiently produced will these revolutionary therapies become widespread.
Increasing the understanding of cells, genes and proteins
An important part of this journey is helping customers look at
biology rather than manipulate it. This is all about diagnosis of disease and using an understanding of how cells, genes and proteins work. GE Healthcare’s goal is to help clinicians make more informed diagnoses that lead to better patient outcomes. With diagnostic products used in X-ray, CT, MRI, SPECT or PET scans, GE Healthcare helps doctors to get a better picture when managing diseases such as cancer, heart disease or Parkinson’s.
Understanding how genetic variations affect disease is critical to the discovery and development of new and more effective therapies for complex diseases such as breast cancer
GE Healthcare Life Sciences in Uppsala
One of the GE Healthcare’s key sites is in Uppsala, Sweden, which has been a global hub for the life sciences
since the 1950s. The Uppsala site has around 1,200 employees working with production, research & development
and with support functions such as marketing. In Umeå, GE Healthcare has a production site that has around 400
Recently GE Healthcare announced a SEK 870 million investment on its manufacturing facility in Uppsala that will
significantly increase the plant’s current production capacity for chromatography resins that are used in protein
purification. At present, the facility produces 250 different types of chromatography resin used in the purification of
more than 90% of the U.S. Food and Drug Administration (FDA) approved biopharmaceuticals.